市場調查報告書
商品編碼
1522738
全球連續血糖監測市場評估:按組成部分、年齡層、糖尿病類型、最終用戶、地區、機會、預測,2017-2031Continuous Glucose Monitoring Market Assessment, By Component, By Age Group, By Diabetes Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
預計2024-2031年期間,全球連續血糖監測(CGM)市場規模將以11.13%的複合年增長率擴大,並預計將持續成長到2031年。連續血糖監測市場是醫療器材產業不可或缺的一部分,也是成長最快的市場之一。糖尿病盛行率的增加、持續血糖監測設備的日益普及、糖尿病監測意識的增強以及技術的進步正在推動市場的發展。
連續血糖監測設備使用血糖水平測量來透過最大限度地減少指尖採血測試來管理糖尿病。透過放置在患者皮膚上或皮膚下的感測器全天連續測量血糖水平。發射器可以與智慧型手錶等穿戴式裝置結合使用,以顯示任何給定時間點的血糖水平變化。也就是說,使用 CGM 進行糖尿病管理簡化了流程,但需要一些時間來適應。使用 CGM 數據時,範圍內時間方法除了計算患者處於所需血糖值測量範圍內的時間之外,還計算血糖高於(高血糖)或低於(低血糖)正常水平的次數。血糖儀可對一個人的血糖值進行單點估計,但 CGM 設備可提供更廣泛的血糖模式視圖。多項研究證明 CGM 設備可以幫助使用者將血糖值保持在一定範圍內,消除低血糖和高血糖,並減少糖尿病相關問題的可能性。也就是說,使用 CGM 是一個長期的解決方案。
隨著糖尿病患者數量的增加,對 CGM 的需求也顯著增加。2,300 萬名糖尿病患者中有 31% 接受胰島素治療,並且可以使用連續血糖監測 (CGM)。美國糖尿病協會推薦CGM作為第1型糖尿病患者治療的黃金標準,也是接受胰島素治療的第二型糖尿病患者的重要裝置。綜上所述,不斷增加的糖尿病患者數量增加了對連續血糖監測設備的需求,這可以顯著改善血糖控制並改善糖尿病患者的健康狀況。隨著糖尿病患者人數的增加,獲得這項技術已成為當務之急。
該報告研究了全球連續血糖監測市場,並提供了市場概述,包括按成分、年齡組、糖尿病類型、最終用戶、區域趨勢以及參與該市場的公司的概況。
Global continuous glucose monitoring market is projected to witness a CAGR of 11.13% during the forecast period 2024-2031, growing from USD 5.75 in 2023 to USD 13.38 in 2031. The continuous glucose monitoring market is an integral part of the medical device industry, accounting for one of the fastest growth rates. Factors are driving the market such as the increasing prevalence of diabetes, the growing adoption of CGM devices, increasing awareness about diabetes monitoring, and technological advancements.
Continuous glucose monitoring devices use glucose level measurements to manage diabetes by minimizing fingerstick tests. Continuous glucose levels are measured throughout the day by a sensor located on or beneath the patient's skin. A transmitter can be used together with some wearable appliance, for instance, a smartwatch, to display changes in blood sugar levels at any given moment of time. Nevertheless, it takes a while to adjust to using a CGM for diabetes management, although it simplifies the process. When CGM data is being utilized, the time-in-range method measures the duration patients have been within the desired glucose levels in addition to a number of times that their glucose has risen above (hyperglycemia) or gone below normal levels (hypoglycemia). A blood glucose meter provides a single-point estimate of a person's blood sugar level, while a CGM device offers a broader perspective on patterns in relation to glucose. It has been demonstrated in several studies that CGM devices help users keep their glucose levels at a constant range, eliminate low and high glucose levels cases, and reduce the chances of coming up with problems that are related to diabetes. Nevertheless, using CGM is a long-term solution.
In March 2024, Roche presented new continuous glucose monitoring technology with artificial intelligence at a conference on Advanced Technologies & Treatments for Diabetes in Italy. The company revealed its Accu-Chek SmartGuide. The device is under research and has not yet been approved for retail sales. There are several characteristics that Abbott and Dexcom CGMs and the Accu-Chek SmartGuide have in common. It has waterproof qualities, a one-step application technique, and a 14-day wear time. On the other hand, unlike some of the newest generation of devices, this CGM needs initial calibration.
Increasing Prevalence of Diabetes Globally
The demand for CGM has increased significantly along with the number of individuals with diabetes. 31% of the 23 million Americans who have diabetes receive insulin treatment, which enables them to use continuous glucose monitoring (CGM). The American Diabetes Association recommends CGM as the gold standard of treatment for those with type 1 diabetes and a crucial device for patients with type 2 diabetes undergoing insulin therapy. In conclusion, the increasing number of people with diabetes is driving demand for continuous glucose monitoring devices, which may significantly improve glucose control and health outcomes for those with the disease. With the increasing number of diabetic people, access to this technology is becoming a priority.
Technological Advancements to Increase Market Demand
The field of CGM technology is continually evolving, with numerous research projects and clinical trials underway. Diabetes is a significant healthcare challenge, and the potential for improving patient outcomes through CGM technology remains effective. Artificial intelligence and machine learning are expected to significantly evolve the role of CGM technology. These advancements will make artificial pancreas systems more precise and sensitive, allowing patients to live their lives naturally without being controlled by their diabetes. Dexcom introduced Dexco ONE+, a real-time continuous glucose monitoring device in Poland, Spain, and Belgium, in February 2024. On February 12th, the business introduced its CGM device in the Netherlands. In the upcoming months, Dexcom plans to introduce Dexcom ONE+ in the Middle East and Africa and other European nations. The Dexcom ONE+ system is made up of a transmitter that transmits CGM data, a water-resistant blood glucose sensor, and an application that works with smartphones to access the Dexcom One app.
Sensors Dominate the Component Segment in the Global Continuous Monitoring Market
Based on components, the sensors account for the highest share in the continuous glucose monitoring market. CGM sensors calculate the glucose level in the fluids between cells, and it is quite comparable to the glucose levels in the blood. Depending on the type of sensor a patient has, it may be necessary to change it every few weeks or at other specified intervals. Depending on the model, disposable CGM sensors need to be changed every 7 to 14 days. A few implanted sensors have a 180-day lifespan. Abbott introduced two over-the-counter glucose monitors in the United States in June 2024, competing against Dexcom's Stelo. Abbott had planned to launch Lingo in the United States after its release in the United Kingdom last year. The device analyzes glucose levels over the course of 14 days and can be worn on the upper arm to assist users in better understanding how their bodies respond to various diets, physical activities, and stresses. Abbott was given FDA approval on May 29th, 2024, to market its Lingo system without a prescription.
Home Care Settings Will Hold the Highest Share in the Forecast Period
In the future, home care settings are expected to witness a significant increase in demand for continuous glucose monitoring (CGM) devices. As the technology develops, with longer sensor wear times, more accuracy, and easier smartphone connection, CGM will become a more alluring alternative for home-based diabetes care. Compared to traditional self-monitoring, continuous glucose monitoring (CGM) is more convenient and is likely to increase adherence since it eliminates the need for fingerstick tests. By enabling patients to actively control their disease and prevent complications, more widespread utilization of CGM has the potential to revolutionize the way diabetes is treated. The use of these devices in homes is expected to increase in the upcoming years as they become more widely available and affordable.
Key Players Landscape and Outlook
Several medical device companies are flourishing in the continuous glucose monitoring market by planning and adopting new strategies. They are complying with new strategic initiatives for medical devices to increase their market presence. New agreements, contracts, acquisitions, mergers, investments, and partnerships are major ways through which they are trying to achieve higher market share.
In May 2024, Sensonics, a globally renowned manufacturer of implantable CGM systems, announced its partnership with Rimidi. The main aim of this collaboration is to formulate the Eversense Remote Patient Monitoring (RPM) Program, which will combine healthcare workflows easily. The Eversense CGM + RPM solution will integrate Rimidi's clinical management platform with Senseonic's durable Eversense sensor.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.